
ExcepGen: A San Francisco-based biotech firm innovating in drug discovery for next-gen therapeutics.
ExcepGen, founded in San Francisco, is an early-stage biotechnology company dedicated to revolutionizing drug discovery. The company's core mission is to address fundamental challenges in the field and develop next-generation therapeutics. ExcepGen specializes in nucleic acid medicines, including gene therapies and vaccines powered by innovative DNA and mRNA technologies. Their market focus is on creating advanced solutions for unmet medical needs, leveraging cutting-edge scientific advancements to improve patient outcomes.
ExcepGen has garnered attention from notable investors and industry leaders due to its pioneering approach in biotechnology. The company has achieved significant milestones in nucleic acid therapeutics, particularly in enhancing the capping, delivery, and manufacturing processes of DNA and mRNA. These advancements have positioned ExcepGen as a key player in the biotech industry, contributing to the development of more effective and targeted treatments. The impact of their work is evident in the potential to transform therapeutic practices and improve global health outcomes.

Exegenesis Bio
exegenesisbio.com

Excision BioTherapeutics

Engage Bio
Exotech Bio

IgGenix
iggenix.com

Algen Biotechnologies
algenbio.com

NExTNet
nextnetinc.com

Amber Bio
amber.bio

Entelexo Biotherapeutics
entelexo.com

Revagenix
revagenix.com

GenEdit
genedit.com

NabGen
nabgen.com

Strm.Bio
strm.bio

Anagenex
anagenex.com

Sixfold Bioscience
sixfold.bio
Companies similar to Excepgen include Exegenesis Bio, Excision BioTherapeutics, Engage Bio and Exotech Bio.
Excepgen was founded in 2018.
Excepgen's headquarters is located in San Francisco, CA, US.
Excepgen's most recent funding round was for $4M (USD) in August 2023.
As of Aug 24, 2023, Excepgen has raised a total of $4.2M (USD).
Excepgen has 6 employees as of Feb 4, 2024.